Faron Pharmaceuticals Oy

FARN · AIM · Health Care · mcap £77m · 36.5p

Beta Briefing, track record and bull & bear case are not ready for Faron Pharmaceuticals Oy yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 58 companies are already wired into a briefing: browse them.

Financials · LTM to 30 Jun 26

Source: results 26 Aug 26 ↗

Revenue: –
Operating profit: −£15.9m
Net income: −£14.4m
Free cash flow: −£17.9m
Net cash: £12.2m
Market cap: £83.2m
EV / EBIT: –
FCF yield: −21.5%
Price / book: 8.4×

Latest half-year · H1 26 vs H1 25 results 26 Aug 26 ↗

Operating profit: −£9.6m
Net income: −£7.4m
Cash from operations: −£10.9m

Extracted automatically from the company's results announcements; check the source before relying on a figure. Not investment advice.

Income statement Cash flow Balance sheet

Annual Half-yearly

Latest report: H1 26 (six months to 30 Jun 26), published 26 Aug 26 · read the results ↗

£m unless stated · newest first · italic = calculated (LTM, H2 = FY − H1) · hover a value for its source

	LTM Jun 26	FY 25
Operating profit	(15.9)	(16.2)
Share-based payments	1.5	1.6
Profit before tax	(14.4)	(23.3)
Tax	–	(0.0)
Net income (owners)	(14.4)	(23.3)
EPS basic	(10.7p)	(20.9p)
EPS diluted	(10.7p)	(20.9p)

	H1 26	vs H1 25	H2 25	H1 25
Operating profit	(9.6)	n/m	(6.2)	(10.0)
Share-based payments	0.5	−13%	1.0	0.6
Profit before tax	(7.4)	n/m	(7.0)	(16.3)
Net income (owners)	(7.4)	n/m	(7.0)	(16.3)
EPS basic	(5.2p)	–	(5.5p)	(15.4p)
EPS diluted	(5.2p)	–	(5.5p)	(15.4p)

	LTM Jun 26	FY 25
Cash from operations	(17.6)	(15.3)
Interest paid	(0.2)	(0.3)
Tax paid	–	(0.0)
Capex (intangibles)	(0.2)	(0.2)
Lease principal paid	(0.1)	(0.1)
Shares issued	35.0	10.4

	H1 26	vs H1 25	H2 25	H1 25
Cash from operations	(10.9)	n/m	(6.6)	(8.7)
Interest paid	(0.0)	−91%	(0.2)	(0.2)
Capex (intangibles)	(0.1)	n/m	(0.1)	(0.1)
Lease principal paid	(0.1)	n/m	(0.1)	(0.1)
Shares issued	34.8	+244%	0.3	10.1

	Latest Jun 26	FY 25
Other intangibles	0.9	1.0
Trade receivables	1.4	3.2
Cash	27.5	10.7
Current assets	29.0	13.9
Total assets	30.8	15.5
Trade payables	2.2	5.8
Borrowings, current	7.4	9.0
Lease liabilities, current	0.1	0.1
Current liabilities	12.1	17.4
Borrowings, non-current	7.9	12.4
Lease liabilities, non-current	0.0	0.1
Total liabilities	20.9	32.1
Total equity	10.0	(16.6)

	H1 26	H2 25	H1 25
Other intangibles	0.9	1.0	0.9
Trade receivables	1.4	3.2	1.2
Cash	27.5	10.7	11.5
Current assets	29.0	13.9	12.7
Total assets	30.8	15.5	14.4
Trade payables	2.2	5.8	5.8
Borrowings, current	7.4	9.0	6.6
Lease liabilities, current	0.1	0.1	0.1
Current liabilities	12.1	17.4	13.5
Borrowings, non-current	7.9	12.4	12.4
Lease liabilities, non-current	0.0	0.1	0.1
Total liabilities	20.9	32.1	28.7
Total equity	10.0	(16.6)	(14.3)

Line items extracted automatically from each results announcement; when a later report restates a period, the later figure is shown. LTM and H2 are calculated from reported periods. Check the source before relying on a figure.

Company filings. Not investment advice.